OncoCyte (NASDAQ:OCX) PT Raised to $4.25 at Needham & Company LLC

OncoCyte (NASDAQ:OCX) had its target price increased by equities researchers at Needham & Company LLC from $3.60 to $4.25 in a research note issued to investors on Wednesday, Benzinga reports. The firm currently has a “buy” rating on the stock. Needham & Company LLC’s price target would suggest a potential upside of 74.18% from the company’s previous close.

Other equities analysts have also recently issued reports about the company. StockNews.com started coverage on OncoCyte in a research note on Wednesday. They set a “sell” rating on the stock. Benchmark reaffirmed a “speculative buy” rating and set a $5.00 target price on shares of OncoCyte in a research report on Monday, April 15th. Finally, Stephens reaffirmed an “equal weight” rating and set a $4.00 target price on shares of OncoCyte in a research report on Wednesday, April 17th. One analyst has rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $4.06.

OncoCyte Trading Down 0.8 %

Shares of OCX opened at $2.44 on Wednesday. OncoCyte has a 12-month low of $2.08 and a 12-month high of $6.20. The business’s fifty day moving average is $2.91 and its 200 day moving average is $3.04.

Insider Activity

In other OncoCyte news, Director Andrew Arno purchased 33,898 shares of the company’s stock in a transaction dated Thursday, April 11th. The stock was purchased at an average price of $2.95 per share, for a total transaction of $99,999.10. Following the transaction, the director now owns 69,054 shares in the company, valued at approximately $203,709.30. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other news, major shareholder Broadwood Partners, L.P. bought 2,420,000 shares of the company’s stock in a transaction that occurred on Thursday, April 11th. The stock was bought at an average price of $2.92 per share, for a total transaction of $7,066,400.00. Following the transaction, the insider now directly owns 4,929,066 shares of the company’s stock, valued at approximately $14,392,872.72. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Andrew Arno bought 33,898 shares of the company’s stock in a transaction that occurred on Thursday, April 11th. The stock was purchased at an average price of $2.95 per share, with a total value of $99,999.10. Following the transaction, the director now directly owns 69,054 shares in the company, valued at $203,709.30. The disclosure for this purchase can be found here. In the last 90 days, insiders acquired 2,457,288 shares of company stock worth $7,176,400. 1.94% of the stock is currently owned by insiders.

OncoCyte Company Profile

OncoCyte Corporation, a molecular diagnostics company, research, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay.